NATCO Pharma Limited: In-Depth Corporate Profile

By Raveendran R | Updated on:

Source: NATCO Pharma Limited Annual Report 2025-26. 📊 Stock Screeners

Metrics for FY 2025-26 Ended Mar 31, 2026
PROFIT & LOSS METRICS (₹ CR)
Revenue
₹437.59 Cr (▼ 8.5%)
Prev Year: ₹478.40 Cr
Operating Profit
₹152.75 Cr (▼ 34.0%)
Prev Year: ₹231.53 Cr
Net Profit
₹137.19 Cr (▼ 27.2%)
Prev Year: ₹188.34 Cr
Operating Margin
34.91 % (▼ 1349 bps)
Prev Year: 48.40 %
PAT Margin
31.35 % (▼ 802 bps)
Prev Year: 39.37 %

📋 Quick Facts / Company Snapshot: NATCO Pharma Limited: In-Depth Corporate Profile

Metric / AttributeCompany Disclosed Detail
Full Corporate NameNATCO Pharma Limited
Corporate Identity Number (CIN)L24230TG1981PLC003201
Year of Incorporation1981
Registered & Corporate HeadquartersNatco House, Road No. 2, Banjara Hills, Hyderabad, Telangana – 500034, India
Chairman and Managing DirectorV.C. Nannapaneni
Vice Chairman and Chief Executive OfficerRajeev Nannapaneni
Chief Financial OfficerAmit Parekh (Appointed w.e.f. February 13, 2026)
Company Secretary & Compliance OfficerVenkat Ramesh Ch.
Consolidated Total Revenue / Income (FY26)₹4,375.90 Crores
Consolidated EBITDA (FY26)₹1,734.10 Crores
Consolidated Profit After Tax (PAT) (FY26)₹1,418.50 Crores (After share of profit of Associate)
Consolidated Net Worth (FY26)₹9,221.10 Crores
Issued & Subscribed Share Capital₹35.80 Crores (17,91,09,870 Equity Shares of ₹2/- each)
Global Workforce Strength5,200+ Employees globally
Permanent Employees on Rolls5,060 (as of March 31, 2026)
Return on Capital Employed (ROCE) (FY26)16.3%
Return on Equity (ROE) (FY26)15.4%
Basic & Diluted Earnings Per Share (EPS) (FY26)₹79.20
Annual Research & Development Spend (FY26)₹408.60 Crores (10.5% of standalone total income)
Credit Ratings (ICRA)Long-Term: AA / Short-Term: A1+
Global PresenceProducts shipped to 50+ Countries across 13 Subsidiaries and 1 Associate

Company Overview

Business Segments

Disclosed Segment & Divisional Revenue Breakdown

Segment / Revenue StreamDisclosed Revenue (₹ in Crores)% of Consolidated Total RevenueOperational Scope & Geographic Focus
Export Formulations – United States2,381.0054.41%Finished dosage oral solids and injectables distributed via partnerships and front-end distribution.
Export Formulations – Brazil287.506.57%Single-source supplier of Everolimus; sales of Apixaban, Carfilzomib, and Oseltamivir.
Export Formulations – Canada251.705.75%2.00
Crop Health Sciences (Agrochemicals)138.203.16%Broad-spectrum insecticides (CTPR), pheromones, herbicides, and crop growth promoters.
Consolidated Total Revenue4,375.90100.00%-202.50
Consolidated Revenue Contribution (FY 2025-26)
┌─────────────────────────────────────────────────────────┐
│ United States Formulations: 54.41%                      │
│ Brazil Formulations: 6.57%                              │
│ Canada Formulations: 5.75%                              │
│ Crop Health Sciences: 3.16%                             │
│ Domestic Formulations, APIs & RoW: 30.11%               │
└─────────────────────────────────────────────────────────┘

Pharmaceuticals Segment

Export Formulations Division

Domestic Formulations Business

Oncology Division
Pharma Specialty Division
Cardiology Division
Diabetology Division
Domestic Therapeutic Architecture
┌─────────────────────────────────────────────────────────┐
│ Oncology: Targeted therapies & cytotoxic oral/injectables│
│ Dynami Specialty: Critical anti-infectives & hospital care│
│ Hygeia Specialty: Hepatology, orthopedics, rare disease │
│ Cardiology: Novel Oral Anticoagulants & cardioprotectives│
│ Diabetology: GLP-1 receptor agonists & oral antidiabetics│
└─────────────────────────────────────────────────────────┘

Active Pharmaceutical Ingredients (API) Division

Agrochemicals Segment (Crop Health Sciences Division)

History and Evolution

Chronological Evolution: 1981 to 2026
┌──────┬─────────────────────────────────────────────────┐
│ 1981 │ Incorporated in Hyderabad, Telangana            │
│ 1983 │ Operations begin at Kothur manufacturing plant  │
│ 1986 │ Operations begin at Nagarjuna Sagar facility    │
│ 1993 │ Chemical division started at Mekaguda           │
│ 1997 │ NATCO Research Centre (NRC) established         │
│ 2003 │ Oncology division launched with VEENAT          │
│ 2006 │ First finished dosage facility in Dehradun      │
│ 2007 │ First commercial ANDA launched in the US        │
│ 2008 │ First Paragraph IV patent challenge filed in US │
│ 2010 │ Cytotoxic API facility opens in Chennai         │
│ 2011 │ Natcofarma do Brasil established in Brazil      │
│ 2012 │ NATCO Pharma Asia established in Singapore      │
│ 2013 │ NATCO Pharma Canada founded in Toronto          │
│ 2014 │ NATCO Pharma Australia established              │
│ 2015 │ Generic Sofosbuvir launched; Guwahati opens     │
│ 2016 │ Generic Oseltamivir capsules launched in the US │
│ 2017 │ Glatiramer Acetate launched; Cardio-Diabetology │
│ 2018 │ Denopsy and generic Posaconazole launched       │
│ 2019 │ Crop Health Sciences launched; Vizag opens      │
│ 2020 │ Visakhapatnam site receives USFDA approval      │
│ 2021 │ Acquisition of Dash Pharmaceuticals (USA)       │
│ 2022 │ CTPR agrochemicals & generic Revlimid launched  │
│ 2023 │ Subsidiaries in Indonesia, UK, and Colombia     │
│ 2024 │ Strategic investments in eGenesis and Cellogen  │
│ 2025 │ 34.88% stake acquired in Adcock Ingram          │
│ 2026 │ Semaglutide & Risdiplam; Adcock stake at 49%    │
└──────┴─────────────────────────────────────────────────┘

Products and Services

Therapeutic Families & Specialty Segments

Oncology & Immunomodulatory Therapeutics

Metabolic & Diabetology Therapeutics

Rare Disease & Specialized Neurological Formulations

Anticoagulant & Cardiovascular Medicines

Anti-Infectives & Viral Therapeutics

Agrochemicals & Crop Protection Solutions

Pipeline Focus Areas
┌─────────────────────────────────────────────────────────┐
│ Peptides & Oligonucleotides: Solid-phase synthesis      │
│ Novel Drug Delivery: Liposomes & nanoparticle isolation │
│ Hot Melt Extrusion: Solubility enhancement platforms    │
│ Para IV Pipeline: 28 patent challenges in the US        │
│ Cell & Gene Therapy: Strategic biotechnology investments│
└─────────────────────────────────────────────────────────┘

Research & Product Pipeline – United States

Pipeline Asset / Brand ReferenceDisclosed Active MoleculeTherapeutic Area / Clinical IndicationDevelopment & Filing Status
KyprolisCarfilzomib (10 mg)Multiple Myeloma / OncologyKey Solo FTF (Para IV)
ImbruvicaIbrutinib (tablet)Chronic Lymphocytic Leukemia / OncologyKey Solo FTF (Para IV)
ZydeligIdelalisibBlood & Bone Marrow Cancer / OncologyKey Solo FTF (Para IV)
LynparzaOlaparibOvarian & Breast Cancer / OncologyKey Solo FTF (Para IV)
OzempicSemaglutide pen (8 mg/3 ml & 2 mg/3 ml)Type 2 Diabetes / EndocrinologyKey Solo FTF (Para IV)
BalversaErdafitinibUrothelial / Bladder CancerKey Solo FTF (Para IV)
WegovySemaglutide (all strengths)Chronic Weight Management / ObesityKey Solo FTF (Para IV)
TabrectaCapmatinibNon-Small Cell Lung CancerKey Solo FTF (Para IV)
EliquisApixabanAnticoagulant / Thrombosis PreventionKey Para IV (NCE-1 Date Filing)
LonsurfTrifluridine / TipiracilMetastatic Colorectal CancerKey Para IV (NCE-1 Date Filing)
YondelisTrabectedinSoft-Tissue Sarcoma & Ovarian CancerKey Para IV (NCE-1 Date Filing)
CalquenceAcalabrutinibMantle Cell Lymphoma / OncologyKey Para IV (NCE-1 Date Filing)
KyprolisCarfilzomib (60 mg/ml)Multiple Myeloma / OncologyKey Para IV (NCE-1 Date Filing)
NurtecRimegepantAcute & Preventive Migraine TherapyKey Para IV (NCE-1 Date Filing)
JevtanaCabazitaxelCastration-Resistant Prostate CancerKey Para IV (NCE-1 Date Filing)
EvrysdiRisdiplamSpinal Muscular Atrophy (SMA)Key Para IV (NCE-1 Date Filing)

Brand Portfolio

Selected Brand Portfolio
┌─────────────────────────────────────────────────────────┐
│ Oncology: VEENAT (Imatinib Mesylate)                    │
│ Hepatology: VELPANAT (Sofosbuvir + Velpatasvir)         │
│ Neurology: DENOPSY (Teriflunomide)                      │
│ Consumer Health: PANADO, BIOPLUS, CITRO-SODA            │
│ Specialized Care: EPIMAX, ALLERGEX, SYNALEVE, PLUSH     │
└─────────────────────────────────────────────────────────┘

NATCO Domestic & International Branded Portfolio

Adcock Ingram Brand Portfolio (South African Associate)

Geographical Presence

Geographic Presence & Manufacturing Network
┌─────────────────────────────────────────────────────────┐
│ United States: NATCO Pharma USA LLC                     │
│ Canada: NATCO Pharma (Canada) Inc.                      │
│ Brazil: NatcoFarma do Brasil Ltda.                      │
│ South Africa: Adcock Ingram Holdings (49% associate)   │
│ Southeast Asia: Singapore, Philippines, Indonesia       │
│ Indian Facilities: Telangana, Andhra, Assam, Tamil Nadu │
└─────────────────────────────────────────────────────────┘

Disclosed Regional Market Revenues

Geography / Commercial DivisionDisclosed Revenue (₹ in Crores)% of Consolidated Total RevenueInfrastructure & Market Scope
United States2,381.0054.41%Commercial front-end (NATCO Pharma USA LLC) and partnership distribution networks.
Brazil287.506.57%Commercial offices, regulatory infrastructure, and hospital tender sales.
Canada251.705.75%2.00
South Africa (Associate Company)59.20Associate Holding (35.75% FY26 / 49% FY27)Midrand corporate headquarters; Clayville and Aeroton manufacturing facilities.
Rest of World & Emerging Markets5.00Balance of Group RevenueOperations in Indonesia, Singapore, Philippines, Colombia, UK, and MENA.

Operational Footprint Across Key Geographies

United States Market

Brazil Market

Canada Market

South African Market

Southeast Asia & Emerging Markets

📊 The Financial Health: The Numbers Simplified

Audited Profit and Loss Performance

Profit & Loss MetricStandalone FY26 (₹ in Crores)Standalone FY25 (₹ in Crores)Consolidated FY26 (₹ in Crores)Consolidated FY25 (₹ in Crores)Consolidated TrendLatest YoY (%)
Total Revenue / Income387.57441.58437.59478.40-8.53%-8.53%
Gross Profit / EBITDA158.60246.56173.41255.05-32.01%-32.01%
EBITDA Margin––39.6%53.3%-13.70 pp–
Finance Costs3.231.963.672.39+53.56%+53.56%
Cash Profit155.37244.60169.74252.66-32.82%-32.82%
Depreciation, Amortisation & Impairment18.9622.0020.6623.52-12.16%-12.16%
Profit Before Tax (PBT) (Before Associate)136.41222.60149.08229.14-34.94%-34.94%
Provision for Tax – Current26.8440.7530.3543.76-30.64%-30.64%
Provision for Tax – Deferred-18.58-3.19-18.46-2.96+523.65%+523.65%
Profit After Tax (PAT) (Before Associate)128.15185.04137.19188.34-27.16%-27.16%
Share of Profit of Associate (Net of Tax)——4.66—New FY26 Inflow–
Profit for the Year Attributable to Shareholders128.15185.04141.85188.34-24.68%-24.68%
PAT Margin (After Associate)––32.4%39.4%-7.00 pp–
Other Comprehensive Income (OCI)2.68-0.1328.74-2.40Turned PositiveN/M
Total Comprehensive Income130.83184.91170.59185.94-8.26%-8.26%
Basic & Diluted EPS (₹)––79.20105.26-24.76%-24.76%

Financial Statement Analysis

Five-Year Net Profit & Margin Progression
┌──────┬──────────────────┬────────────┐
│ FY22 │ ₹1,700 Million   │ 8.3% PAT   │
│ FY23 │ ₹7,153 Million   │ 25.4% PAT  │
│ FY24 │ ₹13,883 Million  │ 33.6% PAT  │
│ FY25 │ ₹18,834 Million  │ 39.4% PAT  │
│ FY26 │ ₹14,185 Million  │ 32.4% PAT  │
└──────┴──────────────────┴────────────┘

Balance Sheet and Capital Structure

Disclosed Balance Sheet & Capital Indicators

Balance Sheet & Capital MetricFY 2024-25FY 2025-26Year-on-Year Change
Consolidated Net Worth7,607.009,221.10+21.22%
Authorised Share Capital₹40.00 Crores (200M shares)₹45.00 Crores (225M shares)+12.50%
Paid-Up Share Capital₹35.80 Crores (179.11M shares)₹35.80 Crores (179.11M shares)Maintained (Face Value ₹2)
Return on Capital Employed (ROCE)30.1%16.3%-13.80 percentage points
Return on Equity (ROE)24.7%15.4%-9.30 percentage points
Total Dividend Paid Out–89.56₹5.00 per share (6.99% standalone PAT)
ICRA Credit Rating: Long-TermAAAAMaintained
ICRA Credit Rating: Short-TermA1+A1+Maintained
Five-Year Consolidated Net Worth Growth (₹ Million)
FY22: 42,636 
FY23: 48,738 
FY24: 58,531 
FY25: 76,070 
FY26: 92,211 

Board of Directors and Leadership Team

Board Governance Structure
┌─────────────────────────────────────────────────────────┐
│ Executive Directors: 4 members (44.44%)                 │
│ Independent Non-Executive: 5 members (55.55%)           │
│ Board Gender Diversity: 11.11%                          │
│ Lead Independent Director: Sri D. Vijaya Bhaskar        │
└─────────────────────────────────────────────────────────┘

Board of Directors Profiles

Sri V. C. Nannapaneni – Chairman and Managing Director

Sri Rajeev Nannapaneni – Vice Chairman and Chief Executive Officer

Sri P.S.R.K. Prasad – Director and Executive Vice President (Corporate Engineering Services)

Dr. D. Linga Rao – Director and President (Technical Affairs)

Sri D. Vijaya Bhaskar – Independent Director & Lead Independent Director

Sri A.D.M. Chavali – Independent Director

Sri Lakshminarayana Bolisetty – Independent Director

Dr. Kantipudi Suma – Independent Director

Sri Nitin Jain – Independent Director

Board Committee Attendance and Composition

Committee NameCommittee Mandate & OversightTotal Meetings FY26Average Attendance (%)
Audit CommitteeFinancial reporting integrity, internal controls, risk management, and auditor review.595.00%
Nomination and Remuneration CommitteeBoard appointments, performance appraisals, and executive remuneration policies.3100.00%
Corporate Social Responsibility CommitteeExecution and allocation of CSR expenditures and community trust programs.3100.00%
Risk Management CommitteePeriodic evaluation of financial, operational, and climate risk matrices.288.89%
Stakeholders Relationship CommitteeShareholder grievance redressal, share transfers, and investor relations.1100.00%
Environmental, Social & Governance CommitteeDecarbonization roadmaps, resource stewardship, and BRSR compliance.1100.00%

Executive Management Team

Subsidiaries, Associates, and Joint Ventures

Subsidiary Financial Details (Form AOC-1)

Subsidiary Legal EntityCountry of IncorporationNATCO Holding (%)Reporting CurrencyDisclosed Turnover (₹ Mn)% of Consol RevenueProfit Before Tax (₹ Mn)Profit After Tax (₹ Mn)Total Assets (₹ Mn)
NatcoFarma do Brasil Ltda.Brazil100%BRL0.005.60%0.000.000.00
NATCO Pharma (Canada) Inc.Canada100%CAD0.005.15%0.000.000.00
NATCO Pharma USA LLCUnited States100%USD0.004.70%-0.00-0.000.00
NATCO Pharma South Africa Prop. Ltd.South Africa100%ZAR0.000.82%0.000.000.00
NATCO Lifesciences Philippines Inc.Philippines100%PHP0.000.32%0.00-0.000.00
NATCO Pharma Asia Pte. Ltd.Singapore100%SGD0.000.32%0.000.000.00
PT. NATCO Lotus FarmaIndonesia100%IDR0.000.16%-0.00-0.000.00
Natco Crop Health Sciences LimitedIndia100%INR0.000.00%-0.00-0.000.00
NATCO Pharma Australia Pty LtdAustralia100%AUD0.000.00%-0.00-0.000.00
NATCO Pharma Inc.United States100%USDNil—-0.00-0.000.00
Time Cap Overseas LimitedMauritius100%USDNil—-0.00-0.000.00
NATCO Pharma UK LimitedUnited Kingdom100%GBPNil—0.000.000.00
NATCO Pharma S.A.S.Colombia100%COPNil—-0.00-0.000.00

Associate Company Performance

Associate Corporate NameCountry of OriginYear-End Holding (%)Carrying Investment Value (₹ Mn)Attributable Net Worth (₹ Mn)Full-Year Disclosed PAT (₹ Mn)Profit Recognized in Consolidation (₹ Mn)
Adcock Ingram Holdings Proprietary LimitedSouth Africa35.75% (49% in FY27)0.000.000.00466 (net of tax, post-acquisition)

Profiles of Primary Subsidiaries and Associate

NatcoFarma do Brasil Ltda.

NATCO Pharma (Canada) Inc.

NATCO Pharma USA LLC

Adcock Ingram Holdings Proprietary Limited

Other Strategic Investments

Investee EntityCountry of IncorporationDisclosed Capital CommitmentPrimary Research / Therapeutic MandateStrategic Rationale & Milestone Status
eGenesisUnited StatesUS$ 8.0 MillionXenotransplantation & Human-Compatible Organ EngineeringDeveloping genetically engineered porcine kidneys and organs; achieved the first human transplant of a gene-edited pig kidney in March 2024.
Cellogen Therapeutics Pvt LtdIndiaUS$ 2.0 Million (Tranches: $1M 2024, $1M 2025)Cellular Engineering & CAR-T Gene TherapiesDeveloping 3rd and 4th generation CAR-T cells for leukemia/lymphoma, and gene therapies for sickle cell disease; holds Indian GMP approval.
Stero TherapeuticsUnited States / GlobalUS$ 1.0 Million (Invested in 2025)Novel Metabolic Disease TherapiesDeveloping clinical therapeutics for rare metabolic diseases, including Cushing’s syndrome and non-alcoholic steatohepatitis (NASH).
NRC-2694 ProgramIndia (Internal Discovery)Internal Development SpendTyrosine Kinase Inhibitor (Oncology)Small molecule developed for head and neck cancer progressing post-pembrolizumab therapy; filed for US Phase II clinical trials.

Physical Properties and Manufacturing Facilities

Industrial Manufacturing Map
┌───────────────────────┬─────────────────────────────────┐
│ Finished Formulations │ Kothur, Telangana               │
│                       │ Nagarjuna Sagar, Telangana      │
│                       │ Visakhapatnam, Andhra Pradesh   │
│                       │ Dehradun, Uttarakhand           │
│                       │ Guwahati, Assam                 │
├───────────────────────┼─────────────────────────────────┤
│ Active Ingredients    │ Mekaguda, Telangana             │
│                       │ Chennai, Tamil Nadu             │
├───────────────────────┼─────────────────────────────────┤
│ Agrochemicals         │ Attivaram, Andhra (Technical)   │
│                       │ Attivaram, Andhra (Formulations)│
├───────────────────────┼─────────────────────────────────┤
│ Corporate & Research  │ Banjara Hills & Sanathnagar     │
└───────────────────────┴─────────────────────────────────┘

Pharmaceutical Formulation Facilities

Kothur Facility (Telangana)

Nagarjuna Sagar Facility (Telangana)

Visakhapatnam Facility (Andhra Pradesh)

Dehradun Facility (Uttarakhand)

Guwahati Facility (Assam)

Active Pharmaceutical Ingredient (API) Facilities

Mekaguda Chemical Division (Telangana)

Chennai Organics Facility (Tamil Nadu)

Crop Health Sciences Manufacturing Facilities

Attivaram Formulations Facility (Andhra Pradesh)

Attivaram Technical Plant (Andhra Pradesh)

Research, Corporate, and International Infrastructure

Founders and Executive Leadership

Investments and Capital Expenditure Plans

Capital Expenditure Priorities
┌─────────────────────────────────────────────────────────┐
│ Internal R&D: ₹4,086 Million (10.5% standalone income)  │
│ Nagarjuna Sagar: Dedicated oncology injectable lines    │
│ Visakhapatnam: High-capacity granulation & spray drying │
│ Kothur: Automated liquid capsule filling lines          │
│ Decarbonization: On-site solar & boiler electrification │
└─────────────────────────────────────────────────────────┘
Five-Year R&D Investment Record
┌──────┬──────────────────┬─────────────────────────────┐
│ FY22 │ ₹2,267 Million   │ 12.8% of Standalone Income  │
│ FY23 │ ₹1,959 Million   │ 8.3% of Standalone Income   │
│ FY24 │ ₹2,694 Million   │ 7.5% of Standalone Income   │
│ FY25 │ ₹3,733 Million   │ 9.1% of Standalone Income   │
│ FY26 │ ₹4,086 Million   │ 10.5% of Standalone Income  │
└──────┴──────────────────┴─────────────────────────────┘

Future Strategy and Growth Levers

Strategic Roadmap
┌─────────────────────────────────────────────────────────┐
│ FY27 Baseline Year: Establishing normalized earnings    │
│ Medium-Term Target: Double-digit growth across 2-3 years│
│ Five Market Pillars: India, US, Brazil, Canada, S. Africa│
│ Technology Focus: Peptides, oligos, NDDS platforms      │
│ Agrochemical Spin-Off: Independent capital allocation   │
└─────────────────────────────────────────────────────────┘

Geographic & Portfolio Diversification

Paragraph IV and Complex Generics Pipeline

Advanced Therapeutic Platforms

Agrochemical Spin-Off Execution

Environmental Sustainability Roadmap

Key Strengths

Key Challenges and Risks

Conclusion and Strategic Outlook

Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.

Official Site: https://www.nseindia.com